ES487923A0 - Un procedimiento para la preparacion de espiro-quinolilludantoinas, utiles como inhibidores de la aldosa-reductasa para el tratamiento de las complicaciones cronicas de la diabetes - Google Patents

Un procedimiento para la preparacion de espiro-quinolilludantoinas, utiles como inhibidores de la aldosa-reductasa para el tratamiento de las complicaciones cronicas de la diabetes

Info

Publication number
ES487923A0
ES487923A0 ES487923A ES487923A ES487923A0 ES 487923 A0 ES487923 A0 ES 487923A0 ES 487923 A ES487923 A ES 487923A ES 487923 A ES487923 A ES 487923A ES 487923 A0 ES487923 A0 ES 487923A0
Authority
ES
Spain
Prior art keywords
quinolilludantoins
aldosa
spiro
diabetes
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES487923A
Other languages
English (en)
Other versions
ES8103090A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES8103090A1 publication Critical patent/ES8103090A1/es
Publication of ES487923A0 publication Critical patent/ES487923A0/es
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES487923A 1979-01-22 1980-01-22 Un procedimiento para la preparacion de espiro-quinolilludantoinas, utiles como inhibidores de la aldosa-reductasa para el tratamiento de las complicaciones cronicas de la diabetes Granted ES487923A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/005,278 US4176185A (en) 1979-01-22 1979-01-22 Spiro-quinolylhydantoins

Publications (2)

Publication Number Publication Date
ES8103090A1 ES8103090A1 (es) 1981-02-16
ES487923A0 true ES487923A0 (es) 1981-02-16

Family

ID=21715098

Family Applications (1)

Application Number Title Priority Date Filing Date
ES487923A Granted ES487923A0 (es) 1979-01-22 1980-01-22 Un procedimiento para la preparacion de espiro-quinolilludantoinas, utiles como inhibidores de la aldosa-reductasa para el tratamiento de las complicaciones cronicas de la diabetes

Country Status (22)

Country Link
US (1) US4176185A (es)
EP (1) EP0014079B1 (es)
JP (1) JPS5840959B2 (es)
KR (1) KR830001940A (es)
AR (1) AR222685A1 (es)
AT (1) AT365588B (es)
AU (1) AU514271B2 (es)
CA (1) CA1140928A (es)
DE (1) DE3060079D1 (es)
DK (1) DK156399C (es)
EG (1) EG15085A (es)
ES (1) ES487923A0 (es)
FI (1) FI69308C (es)
GR (1) GR72408B (es)
IE (1) IE49365B1 (es)
IL (1) IL59177A (es)
NO (1) NO152172C (es)
NZ (1) NZ192650A (es)
PH (1) PH15472A (es)
PT (1) PT70716A (es)
YU (1) YU41692B (es)
ZA (1) ZA80344B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
AU532110B2 (en) * 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
ATE10940T1 (de) * 1981-05-12 1985-01-15 Imperial Chemical Industries Plc Pyrrolderivate.
MX12896A (es) * 1987-09-04 1993-06-01 Pfizer Procedimiento para preparar un compuesto de espiro-heteroazolonas
US5068333A (en) * 1990-03-07 1991-11-26 Pfizer Inc. 6-chloro-3,4-dihydro-pyrano [2,3-b]pyridines having the R configuration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
US3876659A (en) * 1970-09-18 1975-04-08 Sandoz Ag Spiro tricyclic isoindolines
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins

Also Published As

Publication number Publication date
AU5476680A (en) 1980-07-31
KR830001940A (ko) 1983-05-19
DE3060079D1 (en) 1982-01-21
ES8103090A1 (es) 1981-02-16
IE800109L (en) 1980-07-22
NO152172C (no) 1985-08-14
DK156399C (da) 1990-01-08
NO152172B (no) 1985-05-06
GR72408B (es) 1983-11-02
AT365588B (de) 1982-01-25
CA1140928A (en) 1983-02-08
DK156399B (da) 1989-08-14
AR222685A1 (es) 1981-06-15
NZ192650A (en) 1984-04-27
JPS55108873A (en) 1980-08-21
YU41692B (en) 1987-12-31
ATA26780A (de) 1981-06-15
FI69308C (fi) 1986-01-10
PH15472A (en) 1983-01-24
DK24280A (da) 1980-07-23
EG15085A (en) 1986-12-30
FI800163A (fi) 1980-07-23
ZA80344B (en) 1981-02-25
AU514271B2 (en) 1981-01-29
NO794318L (no) 1980-07-23
IE49365B1 (en) 1985-09-18
EP0014079A1 (en) 1980-08-06
FI69308B (fi) 1985-09-30
US4176185A (en) 1979-11-27
YU13180A (en) 1983-01-21
IL59177A (en) 1982-11-30
PT70716A (en) 1980-02-01
JPS5840959B2 (ja) 1983-09-08
EP0014079B1 (en) 1981-11-18
IL59177A0 (en) 1980-05-30

Similar Documents

Publication Publication Date Title
MX5222E (es) Procedimiento para el tratamiento de lactosuero
BR7805735A (pt) Composicao para tratamento de superficies
AR219531A1 (es) Procedimiento para preparar el isomero dextrogiro de un compuesto de espirohidantoina asimetrica
ES498617A0 (es) Procedimiento de preparar complejos cristalinos de inclusion,hormonalmente activos, para el crecimiento de las plantas.
ES490645A0 (es) Un procedimiento para la produccion de un derivado 4-amino- 3-carboxi o ciano-1,2-dihidro-2-oxo-1,8-naftiridina
ES493812A0 (es) Procedimiento para el tratamiento de azufre insoluble.
AR221251A1 (es) Un procedimiento para la preparacion de derivados de 4-piperidino-6,7-dialcoxi-quinazolina
AR211568A1 (es) Un metodo para preparar una composicion para el tratamiento de quemaduras
AR219561A1 (es) Procedimiento para la preparacion de nuevos derivados de 1-piperidino-6,7-dialcoxi-ftalazina utiles como agentes terapeuticos
MX157191A (es) Procedimiento para el tratamiento de aceites usados
MX6053E (es) Procedimiento microbiologico para la preparacion de derivados del sesquiterpeno
AR225666A1 (es) Procedimiento para la produccion de derivados para la produccion de derivados de 1-alquil-1-alquenil,alcoxi o alquil-3-5-alquil,fenil o halo-3-isoxazolilourea
ES487923A0 (es) Un procedimiento para la preparacion de espiro-quinolilludantoinas, utiles como inhibidores de la aldosa-reductasa para el tratamiento de las complicaciones cronicas de la diabetes
MX3635E (es) Procedimiento para la produccion de compuestos de 3-aciloximetilcefem
ES485168A0 (es) Un procedimiento para la preparacion de una composicion far-maceutica util para el tratamiento de la hipercolesteremia.
ES507758A0 (es) Un procedimiento para la preparacion de nuevos derivados de quinoleinetanol o quinoleinpropanol utiles como medicamentos
AR226532A1 (es) Procedimiento para la preparacion de azocompuestos
AR220548A1 (es) Procedimiento para la preparacion de una heterovacuna para el tratamiento terapeutico del sindrome de trichomonas
ES530432A0 (es) Un procedimiento para la preparacion de derivados de pirazolona utiles como inhibidores de lipoxigenasa.
AR219314A1 (es) Procedimiento para la produccion de piensos
AR218937A1 (es) Metodo para el tratamiento de acido fosforico
AR212999A1 (es) Proceso para la preparacion de di-n-propil acetonitrilo
AR220127A1 (es) Procedimiento para la preparacion de d-homopregna-4,8-dieno-3,20-dionas
MX5554E (es) Metodo para el cultivo de basidiomecetes
ES211991Y (es) Aparato ortopedico para facilitar el crecimiento.

Legal Events

Date Code Title Description
MM4A Patent lapsed

Effective date: 19960401